Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $94.00 short put and a strike $89.00 long put offers a potential 7.99% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $94.00 by expiration. The full premium credit of $0.37 would be kept by the premium seller. The risk of $4.63 would be incurred if the stock dropped below the $89.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Intercept Pharmaceuticals Inc.'s 270% Pop: Here's What You Need to Know
Thu, 09 Jan 2014 21:11:50 GMT
Motley Fool – Data monitors halted the trial for Intercept's OCA drug for liver disease. This is what captured investors attention.
Why Pharmacyclics and J&J's Lack of Data Is So Amazing
Thu, 09 Jan 2014 19:16:10 GMT
Motley Fool – Pharmacyclics and Johnson & Johnson's Imbruvica beat GlaxoSmithKline's Arzerra in a head-to-head trial. But by how much?
Dow Today: Johnson & Johnson (JNJ) Higher
Thu, 09 Jan 2014 19:00:00 GMT
TheStreet – The Dow component leading the way higher looks to be Johnson & Johnson (NYSE: JNJ ), which is sporting a 63-cent gain (+0.7%) bringing the stock to $94.79.
Johnson & Johnson Innovation Expands Global Incubator Presence to Israel and Announces Multiple, Diverse, Early-Stage Collaborations with Academia and Biotech
Thu, 09 Jan 2014 18:36:14 GMT
noodls – New Brunswick (January 8, 2014) – Johnson & Johnson Innovation today announced that it is expanding its global incubator presence through a novel collaboration with the Office of the Chief Scientist in …
AstraZeneca plc (ADR) Hopes Farxiga Can Go Far
Thu, 09 Jan 2014 16:43:58 GMT
Motley Fool – A new diabetes approval is better than a rejection, but AstraZeneca has its work cut out.
Also on Market Tamer…
Follow Us on Facebook